Gleason DF (1966) Classification of prostate carcinomas. Cancer Chemother 50:125–128
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2014) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252
Kvale R, Moller B, Wahiqvist R et al (2008) Concordance between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJUI 103:1647–1654
Rapiti E, Schaffar R, Iselin C et al (2013) Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. MBC Urol 13:19
Müntener M, Epstein JI, Henandez DJ et al (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–776
King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90:305–311
Isariyawongse BK, Sun L, Banez L et al (2008) Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology 72:882–886
Joniau S, Spyrantis M, Birganti A et al (2018) Gleason score 6 prostate cancer is not always harmless. Eur Urol Suppl 17(2):e242–e243
Albissini S, Joniau S, Quackels T et al (2017) Current trends in patient enrolment for robotic-assisted laparoscopic prostatectomy in Belgium. Cancer 123(21):4139–4146
European association of urology: guideline on clinical diagnosis of prostate. https://uroweb.org/guideline/prostate-cancer/
McHugh (2012) Interrater reliability: the kappa statistic. Biochem Med 22(3):276–282
Wong AT, Agarwal M, Navo EB, Schwartz D, Schreiber D (2017) Concordance of gleason score on biopsy and after prostatectomy: a SEER databyse analysis. J Clin Oncol 33:50
Evans SM, Bandarage VP, Kronborg C, Earnest A, Millar J, Clouston D (2016) Gleason group concordance between biopsy and radical prostatectomy specimen. A cohort study from prostate Cancer outcome registry – Victoria. Prostate Int 4:145–151
Cumming JA, Ritchie AWS, Goodman CM, McIntyre MA, Chisholm GF (1990) De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease. BJI 65:271–274
Fossati N, Rossi MS, Cucchiara V et al (2017) Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? Urol Oncol 35(4):150.e9–150.15
Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK (2019) Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. BJU Int 124:268–274
Meunier ME, Neuzillet Y, Radulescu C, Cherbonnier C, Hervé JM, Rouanne M, Molinié V, Lebret T (2018) Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence? Prog Urol 28(10):475–481
Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z (2020) Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol 78:29–42
Ahmed HU, Bosaily AE, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group Collaborators (2018) MRI-targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med 378(19):1767–1777
Van Hove A, Savoie PH, Maurin C et al (2014) Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 32:847–858
Kayano PP, Carneiro K, Castilho TML et al (2018) Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Int Braz J Urol 44(6):1106–1113
Truesdale MD, Cheetham PJ, Turk AT et al (2010) Gleason score concordance on biopsy-confirmed prostate cancer: is pathological re-evaluation necessary prior to radical prostatectomy? BJU Int 107:749–754
Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32(1):81–88
Corcoran NM, Hong MK, Casey RG et al (2011) Upgrading in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108:202–210
Comments (0)